07.09.2010
כל הרשימה
שם: דואר אלקטרוני:
להרשם

Regulation



Acucela Launches ENVISION Clarity Trial; Initiates Phase 2 Clinical Trial of Oral Visual

Cycle Modulator in Patients with Dry Age-Related Macular Degeneration

January 13, 2010

Plexxikon Announces First Patient Dosed In Phase 3 Trial of PLX4032 (RG7204) for Metastatic Melanoma
January 10, 2010

FDA Grants Orphan Drug Status for Personalized Lymphoma Vaccine

January 7, 2010

Enzon Opens a Phase 2 Study of PEG-SN38 for Metastatic Breast Cancer
January 6, 2010

VBL Therapeutics Initiates Phase 2 Clinical Trial of VB-201 in Patients with Psoriasis
January 5, 2010

Geron Announces Publication of Data on its Telomerase Inhibitor in Glioblastoma
January 5, 2010

CPEX Pharmaceuticals Announces Completion of Enrollment in Phase 2a Clinical Trial of Nasulin™
December 21, 2009

Successful Completion of Major Portions of PMX 30063 Phase IB Clinical Trial
December 20, 2009

New Phase II Study Showed Trastuzumab-DM1 Shrank Tumors in Women With Highly Advanced HER2-positive Breast Cancer
December 13, 2009

Targacept Initiates Phase 2 Study of TC-5619 in Cognitive Dysfunction in Schizophrenia
December 10, 2009

RegeneRx Announces Final Clinical Results from Phase I Trial with RGN-352
December 9, 2009

First and Only International Study of its Kind Shakes up Metal Biliary Stent Market
December 7, 2009

Gloucester Pharmaceuticals' ISTODAX® Demonstrates Synergistic Activity with Velcade® in B-cell Non-Hodgkin's Lymphoma Cell Lines
December 6, 2009

StemCells, Inc. Welcomes Approval of First Embryonic Stem Cell Lines Under New NIH Guidelines
December 3, 2009

MagForce Nanotechnologies AG applies for European regulatory approval of its Nano-Cancer® therapy
November 30, 2009

Ipsen initiates an Advanced Endometrial Cancer program with BN83495, its first-in-class steroid sulfatase (STS) inhibitor First patient dosed in Phase II
November 25, 2009

StemCells, Inc. Initiates Landmark Trial Targeting "Communication Highway" of the Brain
November 23, 2009

Merck Receives CHMP Positive Opinion for New Fertility Treatment, ELONVA®
November 20, 2009

Genzyme Announces Results of Phase 2/3 Trial of Advanced Phosphate Binder
November 18, 2009

Advanced BioHealing Initiates Largest Prospective Clinical Trial for Venous Leg Ulcers Planned to Date
November 17, 2009

FDA Approves Lysteda to Treat Heavy Menstrual Bleeding
November 13, 2009

Geron Collaborators Publish Data on hESC-Derived Glial Progenitor Cell Therapy in Cervical Spinal Cord Injury
November 11, 2009

Zosano Pharma, Inc. Announces Publication of Positive Phase 2 Study of its ZP-PTH Patch for Osteoporosis Therapy
November 9, 2009
 
Acceleron Pharma Initiates First-in-Human Study of ACE-041, a Novel Angiogenesis Inhibitor, in Patients with Advanced Cancer
November 4, 2009

Pico-Tesla starts pilot study for type 2 diabetes with its proprietary magnetic (Magneceutical™) therapy
November 2nd, 2009

BENZEFOAM™ Emollient Foam Demonstrates Significant Reduction in Propionibacterium acnes in Study Presented at the Fall Clinical Dermatology Conference

 
October 19, 2009

Calistoga Pharmaceuticals Presents Interim Clinical Efficacy Results from Ongoing Clinical Trial of CAL-101 at the International Workshop on Chronic Lymphocytic Leukemia
October 19, 2009 


Targacept Presents Data from Highly Successful Phase 2b Trial of TC-5214 as Augmentation Treatment for Major Depressive Disorder
October 15, 2009

Panenza®* and Humenza®* Influenza A(H1N1) Vaccines Demonstrate Robust Immune

Response after One Dose

October 9, 2009

Positive phase II results for GSK1838262 (XP13512) reported for subjects with post-herpetic neuralgia and a history of inadequate response to gabapentin
October 5, 2009

Harvard Clinical Research Institute Enrolls First Patients into DAPT study to Advance Understanding of Dual Antiplatelet Tharepy Following Drug-Eluting Stent Procedures
October 2nd, 2009

Dapagliflozen Study Demonstrated Significantly Improved Glycemic Control and Weight Reduction in Type 2 Diabetes Patients Inadequately Controlled with Metformin
October 2nd, 2009

Two-year Phase III study shows Novartis oral MS therapy FTY720 significantly reduces relapses and disability progression
September 30, 2009

HIV Vaccine Regimen Demonstrates Modest Preventive Effect in Thailand Clinical Study
September 24, 2009

Stentys discloses results for world’s first clinical study to treat acute myocardial
infarction (AMI) with a self-expanding stent
September 22, 2009

MagForce Nanotechnologies completes patient recruitment for pivotal glioblastoma study
September 22, 2009

Hyperion Therapeutics Receives Orphan Drug Designation for HPN-100 for the Treatment of Hepatic Encephalopathy
September 17, 2009

FDA Clears a Test for Ovarian Cancer
September 11, 2009

NanoBio’s Vaccine Adjuvant Platform Demonstrates Robust Immunity and Cross Protection against Influenza
September 8, 2009

Can-Fite Announces Positive Results from its Psoriasis Phase II Trial with CF101

September 7, 2009

Anticancer Drug Yields Positive Response in People with Advanced or Recurring Skin and Brain Cancer
September 3rd, 2009

Novartis MF59® adjuvanted cell culture-based vaccine shows strong immune response in A(H1N1) clinical trials
September 3rd, 2009

Knopp Neurosciences Receives FDA Fast Track Designation for KNS-760704 in ALS
September 2nd, 2009

Acceleron Pharma's ACE-031 Increases Lean Body Mass in Phase 1 Single Dose Clinical Trial
September 2nd, 2009

Promising Results of Drug Trial Could Herald a Replacement for Popular Blood Thinner
August 31, 2009

Study Shows Otamixaban substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes
August 30, 2009

Health Canada Approves Abbott’s XIENCE V® Drug Eluting Stent
August 24, 2009

Sabril Approved by FDA to Treat Spasms in Infants and Epileptic Seizures
August 21, 2009

4SC Commences Phase II trial in Hepatocellular Carcinoma (HCC) with the HDAC Inhibitor 4SC-201
August 18, 2009

FDA Issues Public Health Notification on Glucose Monitoring Technology
August 14, 2009

Ceragenix Completes Long-Term Antimicrobial Efficacy Test on Treated Silicone Medical Device
August 13, 2009

Patients Begin Enrolling into Investigator-Sponsored Phase 2 Trial of Antigenics’ Oncophage® Cancer Vaccine in Newly Diagnosed Glioma
August 12, 2009

FDA Approves Avastin for the Most Common Type of Kidney Cancer

August 2, 2009

FDA Approves Onglyza for the Treatment of Type 2 Diabetes in the US
July 31, 2009

NHLBI Stops Study of Treatment for Pulmonary Hypertension in Patients with Sickle Cell Disease Due to Safety Concerns
July 28, 2009

A.P. Pharma Announces FDA Acceptance of APF530 New Drug Application for Chemotherapy-Induced Nausea and Vomiting
July 20, 2009

Xeloda®-Oxaliplatin Combination (Xelox) Shown to Be More Effective Than Standard Chemotherapy Regimen In Adjuvant Colon Cancer
July 19, 2009

Targacept’s TC-5214 Achieves All Primary and Secondary Outcome Measures in Phase 2b Trial as Augmentation Treatment for Major Depressive Disorder
July 15, 2009

New Data from Phase III Saturn Study Showed Tarceva Improved Overall Survival When Used Immediately After Initial Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
July 13, 2009

FDA Approves Effient to Reduce the Risk of Heart Attack in Angioplasty Patients
July 11, 2009

Hyperion Therapeutics Receives Special Protocol Assessment Approval from FDA for Pivotal Phase III Trial in Urea Cycle Disorders
July 7, 2009

ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study with TB-402
July 3, 2009

Data Demonstrates Long-Term Reduction in Seizure Frequency with Novel Once Daily Anti-Epileptic Zebinix®
June 29, 2009

Vantia Therapeutics’ lead candidate VA106483 demonstrates positive anti‐diuretic effect in Phase IIa trial in nocturia
June 29, 2009

Positive CHMP Opinion for JAVLOR® in metastatic treatment of bladder cancer after failure of a prior platinum-containing regimen
June 26, 2009

Teva Completes Enrollment in Second Oral Laquinimod Phase III MS Clinical Trial
June 25, 2009

Inotek Pharmaceuticals' Novel Glaucoma Candidate, INO-8875, Significantly Reduces
Intraocular Pressure in Phase 1/2 Study